Ampersand Capital Partners Makes Growth Investment in NanoImaging Services
Ampersand Capital Partners has made a growth equity investment in NanoImaging Services, a leading provider of cryo-electron microscopy (cryo-EM) services to the pharmaceutical and biotechnology communities. Members of the NanoImaging Services management team joined Ampersand in the financing. NanoImaging Services will use this investment to support its worldwide growth initiatives, including expanding microscope capacity and adding complementary services to further serve the needs of existing and future customers. Financial terms of the deal were not disclosed. NanoImaging Services is a specialty contract research organization (CRO) that helps biopharma companies harness the power of... Read More »
Ampersand-Backed Sterling Medical Devices Merges With RBC Medical Innovations
Sterling Medical Devices, a portfolio company of private equity firm Ampersand Capital Partners, announced on February 8 its recapitalization and simultaneous merger with RBC Medical Innovations. RBC brings additional design and development capacity, including expertise in energy-based electromechanical devices, as well as manufacturing capabilities to the combined organization. As part of the transaction, MedTech industry executive David Montecalvo has been appointed CEO of the combined company. Sterling Founder Dan Sterling will remain on the senior leadership team and a board director. RBC Founder Carl Mayer has joined the board of directors. RBC Medical Innovations is a medical device... Read More »
Ampersand Capital Partners Strikes Two Deals
Ampersand Capital Partners, a middle-market private equity firm, had a busy week, announcing two deals back to back. On September 21, the company revealed it acquired GeneWerk GmbH and American Laboratory Products Company, Ltd. for an undisclosed sum. Based in Heidelberg, Germany, GeneWerk GmbH is a cell and gene therapy testing laboratory focused on providing preclinical and clinical trial patient sample analysis services. The company is recognized as a leading provider of vector integration site analysis (ISA) services, a method that was developed by the company’s founders and that the FDA and European Medicines Agency recommend performing after the administration of both... Read More »
CROs and CDMOs are Still Selling Fast
This past week Permira, a global investment firm based in the United Kingdom, spent $2.4 billion for Cambrex Corporation (NYSE: CBM). Cambrex is a premier contract development and manufacturing organization (CDMO) in the small molecule space and provides drug substance, drug product and analytical services across the entire drug lifecycle. The $2.4 billion purchase price includes the company’s net debt, for 4.2x revenue and 16.3x EBITDA, represents a 47.1% premium to Cambrex’s closing price of $40.78 on August 6. The target reported a number of its own acquisitions recently, making the CDMO a more attractive buy. Cambrex acquired Halo Pharma in 2018 and Avista Pharma Solutions... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
